使用LPS选择性介孔聚合物吸附剂进行血液灌流治疗脓毒性休克:一项多中心随机临床试验
这项多中心随机对照试验纳入58例腹腔感染合并脓毒性休克(Sepsis-3)患者,Efferon LPS血液灌流组38例、常规治疗对照组20例,按意向性分析。主要终点为脓毒性休克缓解;EHP组MAP和氧合指数快速显著升高、去甲肾上腺素剂量和SOFA评分逐步下降,累积机械通气撤机显著加快(SHR 2.5,P=0.037),3天死亡率显著降低,但14天和28天生存无显著改善。实验室指标显示EHP组LPS、降钙素原、C反应蛋白、IL-6、肌酐、白细胞和中性粒细胞快速下降,结果提示Efferon LPS血液灌流是缓解脓毒性休克、使临床和致病相关生物标志物正常化的安全操作。
要点
- 腹腔感染脓毒性休克患者使用Efferon LPS血液灌流,累积机械通气撤机较对照组显著加快(SHR 2.5,P=0.037)。
- Efferon LPS组3天死亡率显著低于对照组,但14天和28天生存无显著改善。
- EHP组MAP和氧合指数快速显著升高,去甲肾上腺素剂量和SOFA评分逐步下降。
- 仅Efferon LPS组LPS、降钙素原、C反应蛋白、IL-6、肌酐、白细胞和中性粒细胞快速下降。
- 研究为多中心随机对照试验,EHP组38例、对照组20例,按意向性分析。
适用人群与场景
- 腹腔感染(IAS)合并脓毒性休克(Sepsis-3)的患者。
诊断标准与关键阈值
- 脓毒性休克诊断采用Sepsis-3标准。
处置流程与药物剂量
- Efferon LPS血液灌流组(n=38)接受EHP操作;对照组(n=20)按常规方案治疗、不做EHP。
研究设计与关键结果
- 多中心随机对照试验,Efferon LPS血液灌流组38例、常规治疗对照组20例,按意向性分析。
- 主要终点为脓毒性休克缓解;EHP组MAP和氧合指数快速显著升高,去甲肾上腺素剂量和SOFA评分逐步下降。
- EHP组累积机械通气撤机较对照组显著加快(亚分布风险比2.5,P=0.037)。
- Efferon LPS组3天死亡率显著低于对照组,但14天和28天生存无显著改善。
- 仅Efferon LPS组LPS、降钙素原、C反应蛋白、IL-6、肌酐、白细胞和中性粒细胞快速下降。
证据类型、等级与局限
- 多中心随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,Efferon LPS血液灌流是缓解腹腔感染脓毒性休克、使临床和致病相关生物标志物正常化的安全操作。
指南或共识出处
- 临床试验注册号NCT04827407。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Extracorporeal hemoperfusion (EHP) may improve the course and outcomes of patients with septic shock by targeting cytokines or bacterial endotoxins (lipopolysaccharide [LPS]). Here, we present the results of a multicenter randomized controlled trial ( clinicaltrials.gov/ct2/show/NCT04827407 ) to assess the efficiency and safety of Efferon LPS hemoperfusion cartridges engineered for multimodal targeting LPS, host-derived cytokine, and damage-associated molecule pattern molecules. Patients with intra-abdominal sepsis (IAS) and septic shock (Sepsis-3) were subjected to EHP procedures (n = 38). Control patients with IAS and septic shock (n = 20) were treated using conventional protocols without EHP. The primary end point was resolution of septic shock. Secondary end points included MAP, vasopressor drug dose, partial pressure of arterial oxygen/fraction of inspired oxygen ratio, Sequential Organ Failure Assessment score, length of stay in the intensive care unit, and satisfaction with device use by a 5-point Likert scale. Clinical laboratory tests for a blood cells count, lactate and creatinine concentration, nephelometry test for C-reactive protein, immunochemiluminescent test for procalcitonin, and immunoenzyme analysis for IL-6 concentration were used to monitor the EHP effect versus the control group. Data were analyzed followed the intention-to-treat approach. Wilcoxon STATA 16.0 (StataCorp, College Station, TX) and Excel 2019 with XLStat 2019 add-in (Addinsoft, Paris, France) were used for statistical analysis of the results. The Fine and Gray method of competing risks was used to analyze the primary end point and other data representing the time to event. EHP resulted in a significant and rapid increase in MAP and partial pressure arterial oxygen/fraction of inspired oxygen ratio, progressive decline in norepinephrine doses, and multiorgan deficiency, as evaluated by Sequential Organ Failure Assessment scores. Importantly, EHP led to significantly rapid cumulative mechanical ventilation weaning compared with the control group (subdistribution hazard ratio, 2.5; P = 0.037). Early 3-day mortality was significantly reduced in the Efferon LPS versus control group; however, no significant improvements in survival in 14 and 28 days were revealed. Laboratory tests showed rapidly decreased levels of LPS, procalcitonin, C-reactive protein, IL-6, creatinine, leukocytes, and neutrophils only in the Efferon LPS group. Results demonstrate that EHP with Efferon LPS is a safe procedure to abrogate septic shock and normalize clinical and pathogenically relevant biomarkers in patients with IAS.
参考来源
- Rey S, Kulabukhov VM, Popov A, et al. HEMOPERFUSION USING THE LPS-SELECTIVE MESOPOROUS POLYMERIC ADSORBENT IN SEPTIC SHOCK: A MULTICENTER RANDOMIZED CLINICAL TRIAL. Shock. 2023. PMID: 37018802. doi:10.1097/SHK.0000000000002121
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。